Back
Repligen Corporation (RGEN)
Life Sciences Tools & ServicesRGEN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$143.94
+4.75%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$0.86
ROE
2.5%
Gross margin
53.1%
Debt/Equity
0.33x
Revenue growth
14.8%
Repligen Corporation — company intelligence
Earnings surprises
Q1 2026$0.48 vs $0.39 est+21.9%
Q4 2025$0.49 vs $0.45 est+9.3%
Q3 2025$0.46 vs $0.43 est+7.8%
Q2 2025$0.37 vs $0.40 est-6.8%
Insider activity · 90 days
16 buys3 sellsnet +20,973 shares
Garland Jason KSell 733 · Jun 25, 2026
BARTHELEMY NICOLASBuy 2,239 · May 14, 2026
DAWES KAREN ABuy 995 · May 14, 2026
Recent SEC filings
4 — Insider transaction reportJun 26, 2026
4 — Insider transaction reportMay 18, 2026
4 — Insider transaction reportMay 18, 2026
Latest news
3 Reasons RGEN is Risky and 1 Stock to Buy Instead — Yahoo · 3d ago
Benchmark Upgrades Repligen to Buy, Announces $185 Price Target — Benzinga · 4d ago
Evercore ISI Group Maintains Outperform on Repligen, Raises Price Target to $160 — Benzinga · 4d ago
Is Repligen Corporation (RGEN) A Good Stock To Buy Now? — Yahoo · 1w ago
Here’s Why Repligen Corp. (RGEN) Fell 28% in Q1 — Yahoo · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Repligen Corporation
Weekly undervalued picks (like RGEN)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.